FDC Ltd. — Interim / Quarterly Report 2020

Aug 7, 2020

MANUFACTURERS & EXPORTERS OF FOODS. DRUGS & CHEMICALS

August 07, 2020

BSELimited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001

National Stock Exchange of India Ltd. Exchange Plaza, Plot no. C/l, G Block, Bandra-Kurla Complex, Bandra (E), Mumbai - 400 051

Scrip Code: 531599 Symbol: FOC

Sub.: Press Release

Dear Sir / Madam,

Please find attached herewith the Press Release issued in relation to the Un-audited Standalone and Consolidated Financial Results of the Company for the quarter ended on so" June,2020.

Kindly take the same on record.

Thanking you,

Yours truly, Company Secretary F-8948

MANUFACTURERS & EXPORTERS OF FOODS, DRUGS & CHEMICALS

Foe Limited reports Q1FY21 results

Mumbai, 07 August 2020: FOC Limited (NSE: FOC, BSE: 531599, ISIN: INE258BOI022) reported financials for the first quarter ending 30th June, 2020.

Rs. in Crores	Ql' 20-21	Ql' 19-20	YoY Growth
Operating Revenues	308.18	343.52	-10.29%
EBfTOA	131.55	88.26	49.05%
EBITOA %	42.69	25.69
PBT	121.36	78.09	55.41 %
PAT	91.72	56.22	63.14%
EPS	5.36	3.22	66.46%

Consolidated Ql FY21 FDC reported

Commenting on the results;

The Q 1 performance reflects the impact of the global COVID-19 pandemic and consequent lockdown across markets and is not an indicator of the underlying strength of our business. Our timely risk mitigation initiatives ensured smooth operations of our manufacturing network, thereby maintaining continuous supplies of drugs. In the meantime, we continue to focus on serving our patients and customers, ensuring safety of our employees and business continuity.

We saw the impact of Covid situation and lockdown in the domestic market, while trying to do better in the Domestic market, we have emphasized more on delivering Export orders and preponed the production schedule wherever possible. And worked on reducing/controlling costs.

India Market:

Sale of branded formulations in India for Q1FY21 was Rs. 231.43 crores, a decline of 13.66% over the same quarter last year. Overall sales in India markets accounted for 75.67% of total consolidated sales for the quarter.

FOC has believed in providing quality products at affordable prices. So, to fight Coronavirus and help the society, FDC is planning to launch Favipiravir for the treatment of mild to moderate cases of Covid-19 in India.

CORPORATE OFFICE

REGISTERED OFFICE

: 142-48, S. V. Road, Jogeshwari 0/'1), Mumbai - 400102. INDIA Tel.: +91-22-6291 7900/950/26780652/2653/2656 • Fax: +91-22-2677 3462 E-mail: fdc@fdcindia.com • Website: www.fdcindia.com : 8-8, M.I.D.C. Industrial Area, Waluj - 431 136, Dist. Aurangabad. INDIA

Tel.: 0240-2554407/2554299/2554967 • Fax: 0240-2554299 E-mail: waluj@fdcindia.com • CIN : L24239MH1940PLCOO3176

Foe Limited

Export Formulations Market:

Formulation Sales in the Export market were Rs. 59.26 crores in QIFY21, a decline of3.01% over Q I last year and accounted for 19.34% of total consolidated sales.

The main contributor is the USA market, accounting to 74.72 % of total Export Formulations Sales. FDC is planning to launch Olopatadine ophthalmic solution 0.1 % in the USA market for increasing presence in Ophthalmic Therapy. 1 ANDA to be filed this year apart from 7 approved ANDA's, all in Ophthalmics.

Export API Market:

API Sales in the Export market were Rs. 15.28 crores in QIFY21, a increase of36.36 % over Q I last year and accounted for 4.99 % of total consolidated sales. We are focusing on increasing the Export API sales in the coming year.

ABOUT FDC LTD

Established in 1940, with the dream of building a world class company and vision to make the nation self-reliant in healthcare. FDC carries forward the flaming spirit of its first dream, achieving accreditations from the US-FDA, UK-MHRA, MCC-RSA, and the UAE, to cite a few. FDC is a forerunner in manufacturing and marketing of Oral Rehydration Salts CORS) and Ophthalmics. FDC has also set-up globally approved, multi-location manufacturing facilities for Active Pharmaceuticals Ingredients CAPIs) as well as Finished Dosage Forms. These facilities are located at Roha, Waluj and Sinnar in Maharashtra, Vema in Goa and Baddi in Himachal Pradesh. FDC markets more than 300 products in India and exports many of these to over 50 countries. FDC strives to explore, innovate and integrate solutions with modem technology, empowering talent and expanding healthcare horizons for a better quality of life to millions globally.

Disclaimer

Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties including the impact of Covid-19 and other factors that could cause actual results to differ materially from those suggested by the forwardlooking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, our ability to obtain regulatory approvals, technological changes, fluctuation in earnings, foreign exchange rates, our ability to manage international operations and exports, our exposure to market risks as well as other risks.